CMPS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Compass Pathways (CMPS) appears to be a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including progress in its Phase 3 trials, increasing hedge fund interest, and favorable analyst ratings. Although the RSI indicates overbought conditions, the long-term growth potential and positive sentiment around the company's psilocybin treatment for treatment-resistant depression make it a promising investment.
The MACD is positive and expanding, indicating bullish momentum. RSI is at 82.244, suggesting overbought conditions, which could mean a short-term pullback. Moving averages are converging, signaling potential consolidation. Key resistance levels are at 6.5 and 6.816, with support at 5.476 and 5.16.
Positive topline results from Phase 3 trials (COMP005/
and plans for FDA alignment on NDA submission in Q4
Hedge fund buying has increased by 302.54% in the last quarter.
Favorable analyst ratings and price target increases, with targets ranging from $14 to $
Launch of a grant program to prepare healthcare providers for the psilocybin treatment rollout.
Broader market interest in psychedelics due to policy discussions on ibogaine research.
Overbought RSI levels suggest a potential short-term pullback.
No revenue growth in the latest quarter, indicating reliance on future approvals and commercialization.
High implied volatility (101.91%) could lead to significant price swings.
In Q4 2025, the company reported a net income loss of -$93.88M, which improved by 116.65% YoY. EPS also improved by 55.56% YoY to -0.98. However, revenue and gross margin remain at zero, reflecting the pre-revenue stage of the company.
Analysts maintain a positive outlook, with multiple Buy and Overweight ratings. Recent price targets range from $14 to $22, reflecting confidence in the company's progress and potential FDA approval for its psilocybin treatment.
